Julie is a dedicated resource for summer associates and associates who want to sharpen their legal writing skills. She works one-on-one with lawyers and teaches workshops that address common writing challenges. In Chambers Associate, our associates called Julie "an invaluable asset to the firm."
Women in Law Empowerment Forum awarded Schiff Hardin its 2015 Gold Standard in Recognition of Integration of Women in the Firm for the 3rd straight year. Schiff Hardin was one of only eight firms in the nation to earn a perfect score.
Co-leader of Schiff Hardin’s Intellectual Property Group, Imron T. Aly also serves as co-chair of the firm's Pharmaceuticals and Biologics Patent Litigation Team. He focuses his practice in patent infringement and trade secret misappropriation litigation. He has litigated and managed patent infringement and trade secret matters for pharmaceuticals, medical implants and devices, DNA arrays, mechanical production assemblies, computer business methods and financial trading systems.
Prior to joining Schiff Hardin, Imron was an intellectual property partner in the Chicago office of an international law firm.
Imron's representative matters prior to joining Schiff Hardin include:
Richard Linn American Inn of Court
Guest Lecturer, Patent Litigation, University of Michigan (2011, 2013)
The Supreme Court recently agreed to hear a challenge to the current interpretation of the venue statute in patent infringement cases.
Thirty-nine Schiff Hardin attorneys have been selected for inclusion on the 2017 Illinois Super Lawyers and Rising Stars lists.
Schiff Hardin is pleased to announce that Benchmark Litigation’s ninth edition honored the firm as a “Recommended Firm” in Illinois.
Schiff Hardin’s pharma and life sciences patent litigation team, lead by partner Imron T. Aly, recently secured a preliminary injunction in federal court.
Supreme Court Holds that Decision to Institute IPR is Non-appealable and PTAB’s “Broadest Reasonable Construction” Standard for Claim Construction is Lawful
Imron T. Aly, Sailesh K. Patel, and Clay A. Tillack have been named Illinois IP Stars and Schiff Hardin received the coveted “High Recommended” classification in the Illinois IP Stars Patent Contentious category.
BTI’s Power Ranking 2016 recognized Schiff Hardin in its top category—Clientopia®—for the firm’s work on behalf of the pharmaceutical industry.
Trade secrets now enjoy the same type of federal protection afforded other forms of intellectual property, like trademarks, copyrights and patents.
The Super Lawyers selection methodology includes a statewide nomination process, peer review by practice area, and independent research on candidates.
Imron has represented indigent clients in trademark and copyright, contract dispute, landlord-tenant, prisoner rights and elder abuse matters.
Metropolitan Tenants Organization
Former Board Member
Thomson Reuters (2017)
Benchmark Litigation (2017)
Managing Intellectual Property (2016)
BTI Power Ranking (2016)
Thomson Reuters (2016)
Thomson Reuters (2015)
Managing Intellectual Property Magazine (2015)
Globe Business Media Group's The World’s Leading Patent Practitioners (2014, 2015)
Chambers USA: America’s Leading Lawyers for Business (2014)
Euromoney's Benchmark Litigation (2013, 2014)
Shortly after approving the first biosimilar under the abbreviated approval pathway created by the Biologics Price Competition and Innovation Act of 2009 (“BPCIA”), the FDA has recently issued 3 final guidances regarding biosimilars. Biological products, or “biologics,” are pharmaceutical products created from biological sources. Unlike chemically synthesized pharmaceuticals, biologics are isolated from natural sources, and … Continue Reading
Schiff Hardin’s pharma and life sciences patent litigation team, led by partner Imron T. Aly, recently secured a preliminary injunction in federal court. Representing generic drug manufacturer Fresenius Kabi USA, LLC, our team convinced the judge to bar our client’s competitor from launching a generic version of levothyroxine, our client’s patented treatment formulation.